This is a preview of subscription content, log in via an institution to check access.
References
Davies HA, Lennard L, Lilleyman JS (1993) Variable mercaptopurine metabolism in children with leukaemia: a problem of non-compliance? BMJ 306: 1239–1240
Lennard L, Lilleyman JS, Van Loon JA, Weinshilboum RM (1990) Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336: 225–229
Chocair PR, Duley JA, Simmonds HA, Cameron JS (1992) The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation 53: 1051–1056
McLeod HL, Miller DR, Evans WE (1993) Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 341: 1151
Zimm S, Collins JM, Riccardi R, O'Neill D, Narang PK, Chabner B, Poplack DG (1983) Variable bioavailability of oral mercaptopurine. N Engl J Med 308: 1005–1009
Lennard L (1992) The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 43: 329–339
Kerstens PJSM, Stolk JN, Hilbrands LB, Putte LBA van de De Abreu RA, Boerbooms AMT (1993) 5-nucleotidase and azathioprine-related bone-marrow toxicity. Lancet 342: 1245–1246
Lilleyman JS, Lennard L (1994) Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 343: 1188–1190
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McLeod, H.L. Commentary on interactions between 6-mercaptopurine therapy and thiopurine-methyl-transferase (TPMT) activity. Eur J Clin Pharmacol 48, 85–86 (1995). https://doi.org/10.1007/BF00202180
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00202180